Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C-lowering therapy in statin-intolerant patients, with evidence from our own clinical practices.

Original languageEnglish
Pages (from-to)159-165
JournalClinical Cardiology
Volume41
Issue number1
DOIs
Publication statusPublished - 24 Jan 2018

Fingerprint Dive into the research topics of 'Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience'. Together they form a unique fingerprint.

Cite this